MHT Group

The MHT project was born in 1991 in Verona, Italy, and then extended in 1995 with the creation of MHT OR AG in Swiss (Zurich). It's an advanced research project in the optic's field, carried out by a vanguard team of technicians and engineers, with the goal to develop new technologies to be applied on the electro-medical field.

The big financial commitment leaded to a first and encouraging result in 1998, with the spectrophotometer "SpectroShade", a state of the art idea and instrument, immediately patented. After a first positive market experience in the dental sector, that recently achieved an acknowledgement from the Colgate-Palmolive corporation, in 2000 started an ambitious cooperation in dermatological studies with the Istituto Nazionale per lo Studio e la Cura dei Tumori (INT), to obtain an instrument for the early melanoma diagnosis.

The goals reached in this cooperation were excellent, and INT presented those results towards the academic and scientific world in the international meeting on 20 june 2003. Year after year this cooperation lead to even better results, as our unique instrument give evidence.

>Soon will be ready another instrument useful to orientate the doctor in the therapeutic treatment of aesthetic vascular diseases.

Nowadays each MHT instrument is the state of the art in spectrophotometry applied to medical diagnosis. MHT AG continuously develop and studies new instrument and search for new fields of application.

MHT S.p.A. has a social capital of 7 millions Euro, controlled by Gobbetti family, together with private bank Aletti Merchant (Gruppo Banco Popolare di Verona e Novara) and Mediocredito del Trentino Alto Adige.